Description

Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics.

Figure 28

Chart

Source Paper

The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant …

Nutrients (2020)

PMID: 32635661

DOI: 10.3390/nu12071999

Cite This Figure

![Figure 28: Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics.]()

> Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." *Nutrients*, 2020. PMID: [32635661](https://pubmed.ncbi.nlm.nih.gov/32635661/)

<figure>
  <img src="" alt="Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics." />
  <figcaption>Figure 28. Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics.<br>  Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32635661/">32635661</a></figcaption>
</figure>

Preuves associées

Bifidobacterium longum pour Irritable Bowel Syndrome (IBS)

Note B · 4 études

Galactooligosaccharides (GOS) pour Irritable Bowel Syndrome (IBS)

Note B · 3 études

Lactobacillus acidophilus pour Irritable Bowel Syndrome (IBS)

Note B · 3 études

Fructooligosaccharides (FOS) pour Irritable Bowel Syndrome (IBS)

Note D · 2 études